Anika Therapeutics annual gross margin
2018
2019
2020
2021
2022
2023
2024
2025
Anika Therapeutics Gross Margin Growth & History (ANIK)
Anika Therapeutics's gross margin was 56.56% for fiscal 2025.
View full Anika Therapeutics company overviewAnika Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 56.56% | −6.82 pp |
| 2024 | 2024-12-31 | 63.38% | −4.94 pp |
| 2023 | 2023-12-31 | 68.33% | +4.00 pp |
| 2022 | 2022-12-31 | 64.33% | +8.21 pp |
| 2021 | 2021-12-31 | 56.12% | +3.21 pp |
| 2020 | 2020-12-31 | 52.91% | −22.01 pp |
| 2019 | 2019-12-31 | 74.92% | +4.55 pp |
| 2018 | 2018-12-31 | 70.37% | — |
Anika Therapeutics quarterly gross margin
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 65.15% | +14.25 pp |
| Q1 2026 | 2026-03-31 | 64.15% | +8.05 pp |
| Q4 2025 | 2025-12-31 | 62.65% | +6.68 pp |
| Q3 2025 | 2025-09-30 | 56.02% | −9.64 pp |
| Q2 2025 | 2025-06-30 | 50.90% | −15.79 pp |
| Q1 2025 | 2025-03-31 | 56.10% | −9.28 pp |
| Q4 2024 | 2024-12-31 | 55.96% | −4.19 pp |
| Q3 2024 | 2024-09-30 | 65.66% | +0.26 pp |
| Q2 2024 | 2024-06-30 | 66.69% | +6.45 pp |
| Q1 2024 | 2024-03-31 | 65.38% | +8.81 pp |
| Q3 2023 | 2023-09-30 | 60.16% | −2.54 pp |
| Q2 2023 | 2023-06-30 | 65.40% | +5.97 pp |
| Q1 2023 | 2023-03-31 | 60.23% | +9.61 pp |
| Q3 2022 | 2022-09-30 | 56.57% | −1.66 pp |
| Q2 2022 | 2022-06-30 | 62.69% | +8.13 pp |
| Q1 2022 | 2022-03-31 | 59.42% | −1.74 pp |
| Q4 2021 | 2021-12-31 | 50.62% | −0.60 pp |
| Q3 2021 | 2021-09-30 | 58.23% | +3.51 pp |
| Q2 2021 | 2021-06-30 | 54.56% | +9.77 pp |
| Q1 2021 | 2021-03-31 | 61.16% | +1.28 pp |
| Q4 2020 | 2020-12-31 | 51.22% | — |
| Q3 2020 | 2020-09-30 | 54.72% | — |
| Q2 2020 | 2020-06-30 | 44.79% | — |
| Q1 2020 | 2020-03-31 | 59.88% | — |
Anika Therapeutics gross margin trends
Over the last five reported fiscal years, Anika Therapeutics's gross margin increased from 52.91% to 56.56%, a change of +3.65 percentage points. The latest reported quarter, Q2 2026, shows 65.15%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anika Therapeutics filings at SEC.gov ↗